What we do
Business Areas
Bioprinting
In vitro human tissue models that reduce testing costs and animal testing in the cosmetics, chemical, pharmaceutical and household industries.
Bioprinting
In vitro human tissue models that reduce testing costs and animal testing in the cosmetics, chemical, pharmaceutical and household industries.
Learn more
Learn more
Biosciences
Providing user-friendly instruments to bring efficiency and speed to multiple application areas.
Biosciences
Providing user-friendly instruments to bring efficiency and speed to multiple application areas.
Learn more
Learn more
Bioautomation
Accelerating development and manufacturing of diagnostic and bioanalysis test platforms.
Bioautomation
BICO consists of several subsidiaries organized into three business areas. Together, we aim to reduce the world’s organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology.
BICO consists of several subsidiaries organized into three business areas. Together, we aim to reduce the world’s organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology.
Products
With a commitment to quality and innovation, our technologies, products and services have contributed to revolutionary advancements in the life science industry.
With a commitment to quality and innovation, our technologies, products and services have contributed to revolutionary advancements in the life science industry.
Sustainability
BICO’s sustainability agenda connects bioconvergence with three different perspectives that define our operations with UN Sustainability Development Goals.
As of December 2021, BICO is an official signatory of the UN Global Compact Sustainability Development Goals and the Ten Principles of the United Nations Global Compact.
100
+
Animals saved
100
+
Animals saved
BICO’s efforts pushing for animal-free testing, already saving more than 100,000 animal lives, is in step with
recent legislation.
In December 2022, The U.S. Congress passed the FDA Modernization Act 2.0. This means that animal testing will no longer be required for market approval.
A historic milestone in the acceptance of alternatives to animal models in drug discovery. Alternatives that capture human physiology better, that are more ethical, sustainable and most importantly can accelerate the discovery of life changing therapies.
